Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report

Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report

Abstract Background The programmed cell death 1 (PD-1) inhibitor pembrolizumab is a promising agent for treatment of several different malignancies, but as with all immunotherapy there is a potential risk of immune-related adverse events. Adrenocorticotropic hormone (ACTH) deficiency and hypophysiti...

Full description

Bibliographic Details
Main Authors: Sho Tanaka, Masaru Kushimoto, Tsukasa Nishizawa, Masahiro Takubo, Kazutaka Mitsuke, Jin Ikeda, Midori Fujishiro, Katsuhiko Ogawa, Ichiro Tsujino, Yutaka Suzuki, Masanori Abe
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Adrenal insufficiency
Adrenocorticotropic hormone deficiency
Immunotherapy
Pembrolizumab
Programmed cell death 1
Online Access:https://doi.org/10.1186/s40842-019-0092-9

Internet

https://doi.org/10.1186/s40842-019-0092-9

Similar Items